Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Effect of Cannabidiol on Markers of Systemic and Pulmonary Inflammation in People with Chronic Obstructive Pulmonary Disease
EF 2021-22
Résumé
Chronic obstructive pulmonary disease (COPD) affects 17% of Canadians aged 40 years, and is characterized by abnormal circulating levels of systemic and lung-specific inflammatory biomarkers, which increase the risk of adverse health outcomes, including exacerbations and comorbidities (e.g., cardiovascular disease [CVD]). Effective management of inflammation in COPD remains a challenge for healthcare providers. Cannabidiol (CBD) is the main non-psychoactive phytocannabinoid of the Cannabis sativa plant that is receiving progressively greater attention for its potential anti-inflammatory properties. However, the effect of CBD therapy on biomarkers of inflammation in COPD is unknown and represents the focus of our research. We hypothesize that CBD therapy will decrease circulating levels of C-reactive protein (CRP), fibrinogen, TNF-α, interleukin (IL)-6, IL-8 and surfactant protein-D (SPD), and increase circulating levels of Clara cell protein-16 (CC-16). Twenty-four adults (12 males, 12 females) aged 40 years with COPD will be recruited. Following a one-week baseline control (pre-CBD) period, participants will be randomized in a 1:1 ratio to receive either 3 or 6 mg/kg/day of CBD isolate for a period of four weeks, where CBD will be given by mouth in an open-label manner. Serum concentrations of CRP, fibrinogen, TNF-α, IL-6 and IL-8 (systemic inflammatory biomarkers) and plasma concentrations of CC-16 and SP-D (lung-specific inflammatory biomarkers) will be measured and compared at multiple time points during the baseline and treatment periods. The anticipated results of this study will provide preliminary evidence on the efficacy of oral CBD as a novel anti-inflammatory therapy in COPD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467254
Name
Russell Emily L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of Cannabidiol on Markers of Systemic and Pulmonary Inflammation in People with Chronic Obstructive Pulmonary Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cannabidiol; Chronic Obstructive Pulmonary Disease; Inflammation; Pulmonary; Systemic; Therapeutic
Abstract
Chronic obstructive pulmonary disease (COPD) affects 17% of Canadians aged 40 years, and is characterized by abnormal circulating levels of systemic and lung-specific inflammatory biomarkers, which increase the risk of adverse health outcomes, including exacerbations and comorbidities (e.g., cardiovascular disease [CVD]). Effective management of inflammation in COPD remains a challenge for healthcare providers. Cannabidiol (CBD) is the main non-psychoactive phytocannabinoid of the Cannabis sativa plant that is receiving progressively greater attention for its potential anti-inflammatory properties. However, the effect of CBD therapy on biomarkers of inflammation in COPD is unknown and represents the focus of our research. We hypothesize that CBD therapy will decrease circulating levels of C-reactive protein (CRP), fibrinogen, TNF-α, interleukin (IL)-6, IL-8 and surfactant protein-D (SPD), and increase circulating levels of Clara cell protein-16 (CC-16). Twenty-four adults (12 males, 12 females) aged 40 years with COPD will be recruited. Following a one-week baseline control (pre-CBD) period, participants will be randomized in a 1:1 ratio to receive either 3 or 6 mg/kg/day of CBD isolate for a period of four weeks, where CBD will be given by mouth in an open-label manner. Serum concentrations of CRP, fibrinogen, TNF-α, IL-6 and IL-8 (systemic inflammatory biomarkers) and plasma concentrations of CC-16 and SP-D (lung-specific inflammatory biomarkers) will be measured and compared at multiple time points during the baseline and treatment periods. The anticipated results of this study will provide preliminary evidence on the efficacy of oral CBD as a novel anti-inflammatory therapy in COPD.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Russell, Emily L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~